Search Results - "Murage, Mwangi"

Metabolic syndrome and total cancer mortality in the Third National Health and Nutrition Examination Survey by Gathirua-Mwangi, Wambui G., Monahan, Patrick O., Murage, Mwangi J., Zhang, Jianjun

“…Purpose Although metabolic syndrome incidence has substantially increased during the last few decades, it largely remains unclear whether this metabolic…”
Get full text

Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review by Murage, Mwangi J, Tongbram, Vanita, Feldman, Steven R, Malatestinic, William N, Larmore, Cynthia J, Muram, Talia M, Burge, Russel T, Bay, Charles, Johnson, Nicole, Clifford, Sarah, Araujo, Andre B

“…Proper adherence and persistence to medications are crucial for better quality of life and improved outcomes in rheumatoid arthritis (RA), psoriasis (PsO), and…”
Get full text

Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings by Blauvelt, Andrew, Shi, Nianwen, Somani, Najwa, Burge, Russel, Zhu, Baojin, Ridenour, Terri L., Lew, Carolyn R., Zimmerman, Nicole M., Atiya, Bilal, Murage, Mwangi J.

“…Real-world data on long-term treatment patterns associated with interleukin-17A inhibitors in plaque psoriasis are lacking. To compare ixekizumab or…”
Get full text

Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab by Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Malatestinic, William N., Lin, Chen-Yen, Lew, Carolyn R., Zimmerman, Nicole M., Goldblum, Orin M., Zhu, Baojin, Murage, Mwangi J.

“…Real-world data on treatment patterns associated with use of interleukin-17A inhibitors in psoriasis are lacking. To compare treatment patterns between…”
Get full text

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry by Lockshin, Benjamin, Cronin, Angel, Harrison, Ryan W., McLean, Robert R., Anatale‐Tardiff, Laura, Burge, Russel, Zhu, Baojin, Malatestinic, William N., Atiya, Bilal, Murage, Mwangi J., Gallo, Gaia, Strober, Bruce, Van Voorhees, Abby

“…To compare drug survival of ixekizumab to other IL‐17 inhibitors (IL‐17i) and TNF inhibitors (TNFi) among patients with psoriasis (PsO) in a real‐world…”
Get full text

Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases by Leonardi, Craig, Zhu, Baojin, Malatestinic, William N., Eastman, William J., Guo, Jiaying, Murage, Mwangi J., Choong, Casey Kar-Chan, Burge, Russel, Blauvelt, Andrew

“…Introduction Limited real-world data are available comparing multiple biologics on their adherence, persistence, and the use of concomitant biologics in the…”
Get full text

Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient's perspective by Korman, Neil J., Malatestinic, William, Goldblum, Orin M., Murage, Mwangi J., Renda, Lisa, Lin, Chen-Yen, Lucas, James, Middleton, Chloe, Lobosco, Steven

“…Psoriasis is characterized by thick and scaly plaques. The Dermatology Life Quality Index (DLQI) and Physician Global Assessment (PGA) can be used to define…”
Get full text

Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis by Murage, Mwangi J., Gilligan, Adrienne M., Tran, Oth, Goldblum, Orin, Burge, Russel, Lin, Chen-Yen, Qureshi, Abrar

“…Objectives: To describe ixekizumab treatment patterns, all-cause healthcare utilization, and costs among psoriasis patients. Methods: Adults diagnosed with…”
Get full text

Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study by Blauvelt, Andrew, Shi, Nianwen, Murage, Mwangi, Ridenour, Terri, Lew, Carolyn, Somani, Najwa, Zhu, Baojin, Zimmerman, Nicole, Kern, Scott, Burge, Russel

“…There is a paucity of long-term real-world evidence comparing the effectiveness of ixekizumab (IXE) and adalimumab (ADA). We compared real-world treatment…”
Get more information

Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs by Murage, Mwangi J, Princic, Nicole, Park, Julie, Malatestinic, William N, Zhu, Baojin, Atiya, Bilal, Kern, Scott A, Stenger, Keri B, Sprabery, Aubrey Trevelin, Ogdie, Alexis

“…Biologic and targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies are used in management of psoriatic arthritis (PsA). Although previous…”
Get full text

Evaluation of Changes in Skin and Joint Outcomes and Associated Treatment Changes in Psoriatic Arthritis (PsA): Experience From the Corrona PsA/SpA Registry by Mease, Philip J., Etzel, Carol J., Huster, William J., Armstrong, April W., Muram, Talia M., Lisse, Jeffrey, Rebello, Sabrina, Dodge, Rhiannon, Murage, Mwangi J., Greenberg, Jeffrey D., Malatestinic, William N.

“…Objective. To characterize skin severity and joint activity outcomes and associated treatment changes in patients with psoriatic arthritis (PsA) through 12…”
Get full text

Adult BMI change and risk of Breast Cancer: National Health and Nutrition Examination Survey (NHANES) 2005–2010 by Gathirua-Mwangi, Wambui G., Zollinger, Terrell W., Murage, Mwangi J., Pradhan, Kamnesh R., Champion, Victoria L.

“…Objective Breast cancer is the second leading cause of cancer mortality among women in the developed world. This study assessed the association between…”
Get full text

Disease response and patient-reported outcomes among initiators of ixekizumab by Shahriari, Mona, Harrison, Ryan W., Burge, Russel, Lin, Chen-Yen, Malatestinic, William N., Goldblum, Orin M., McLean, Robert R., Crabtree, Margaux M., O'Brien, Jacqueline, Grace, Elsie L., Murage, Mwangi J.

“…There is limited real-world evidence on using ixekizumab in psoriasis patients. Therefore, we characterized patients with psoriasis initiating ixekizumab and…”
Get full text

Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry by Wu, Jashin J, Harrison, Ryan W, Zhu, Baojin, Goldblum, Orin M, Malatestinic, William N, Burge, Russel, Murage, Mwangi J

“…Real-world data on patients newly initiating ixekizumab is limited. Our study describes the characteristics of patients who initiated ixekizumab and other…”
Get full text

Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity by Murage, Mwangi J., Anderson, Amanda, Casso, Deborah, Oliveria, Susan A., Ojeh, Clement K., Muram, Talia M., Merola, Joseph F., Zbrozek, Art, Araujo, Andre B.

“…Purpose: Describe treatment patterns by disease severity among biologic-treated psoriasis patients. Materials and methods: We selected our study cohort in the…”
Get full text

Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab by Blauvelt, Andrew, Shi, Nianwen, Zhu, Baojin, Burge, Russel, Malatestinic, William N, Lin, Chen-Yen, Lew, Carolyn R, Zimmerman, Nicole M, Goldblum, Orin M, Murage, Mwangi J

“…As more biologics become available for the treatment of psoriasis (PsO), there is a lack of direct comparisons of health care costs between patients who are…”
Get full text

Real‐World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study by Murage, Mwangi J., Princic, Nicole, Park, Julie, Malatestinic, William, Zhu, Baojin, Atiya, Bilal, Kern, Scott A., Stenger, Keri B., Sprabery, Aubrey Trevelin, Ogdie, Alexis

“…Objective To describe adherence, persistence, discontinuation, restarting, switching, dosing, and health care costs among patients with psoriatic arthritis…”
Get full text

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab by Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Malatestinic, William N, Lin, Chen-Yen, Lew, Carolyn R, Zimmerman, Nicole M, Goldblum, Orin M, Zhu, Baojin, Murage, Mwangi J

“…There is lack of real-world treatment pattern comparison data between ixekizumab and adalimumab which are approved for the treatment of moderate-to-severe…”
Get full text

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months by Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Somani, Najwa, Ridenour, Terri L., Zhu, Baojin, Atiya, Bilal, Lew, Carolyn R., Zimmerman, Nicole M., Murage, Mwangi J.

“…Introduction Real-world data comparing effectiveness of ixekizumab (IXE) and secukinumab (SEC) among biologic-experienced patients are limited. This study…”
Get full text

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry by Lockshin, Benjamin, Harrison, Ryan W., McLean, Robert R., Crabtree, Margaux M., Konicek, Bruce W., Zhu, Baojin, Malatestinic, William N., Atiya, Bilal, Murage, Mwangi J., Burge, Russel T.

“…Introduction The aim of this work is to describe real-world biologic-experienced psoriasis patients initiating ixekizumab by prior biologic therapy status and…”
Get full text